Dr Feng, Yibin - 香港大學中醫藥學院 20180110.pdfof Integrative Medicine (IF 1.059), Journal of Alternative and Complementary Medicine (IF1.464), Molecular and Cellular Biochemistry

1

Curriculum Vitae in English and Chinese

Dr Feng, Yibin (馮奕斌) Associate Professor, Associate Director (Education),

School of Chinese Medicine,

Li Ka Shing Faculty of Medicine,

The University of Hong Kong

CONTACT INFORMATION Address: School of Chinese Medicine, The University of Hong Kong

10 Sassoon Road, Pokfulam, Hong Kong

Tel: (852) 2589 0482

Fax: (852) 2872 5476

Email: [email protected]

LANGUAGES SPOKEN

Mandarin, English, Cantonese and Japanese

LANGUAGES WRITTEN

Chinese, English, and Japanese

AREAS OF EXPERTISE

Chinese Materia Medica, Pharmacology and toxicology of Chinese medicines; Cancer, metabolic

diseases, liver and kidney diseases; Chinese Medicine education

ACADEMIC QULIFICATION

BMed, MMed Course (Yunnan TCM, China), PhD (Hokkaido University School of Medicine, Japan)

CURRENT PROFESSIONAL SERVICES

- Associate Professor, Associate Director (Education), School of Chinese Medicine, The University of Hong Kong;

- Panel-member of Chinese medicine for education of Chinese medicine in Hong Kong Chinese Medicine Council;

- Panel-member of Chinese Medicines in Hospital Authority of Hong Kong;

- Panel-member of Chinese Medicine (Pharmaceutical) Committee in Hospital Authority of Hong Kong;

- Panel-member of Use of Proprietary Chinese Medicine Steering Committee in Hospital Authority of Hong Kong;

- Panel-member of Chinese medicine experts for registration of proprietary Chinese medicines in Hong Kong Chinese

mailto:[email protected]

2

Medicine Council;

- Organizing Committee member for International Conference & Exhibition of the Modernization of Chinese

Medicine & Health Products (ICMCM) (Annual Conference, 2005-present);

- Joint-Chairman for International Conference & Exhibition of the Modernization of Chinese Medicine & Health

Products (ICMCM) (2013, 2014, Hong Kong);

- Convenor of academic advisory board (2007) and organizing committee for HK-Macao postgraduate Symposium on

Chinese Medicine (Annual Symposium2005-2013, Hong Kong)

- Executive Chairman for The third international symposium and the third national annual conference on dietotherapy

and Chinese medicated diet (2012, Hong Kong)

- External reviewer for Bachelor of Science (Hons) Chinese Medicine Program at International Medical University,

Malaysia (2012-present)

- WHO observer for Regional Launching and Workshop on Implementing the Regional Strategy for Traditional

Medicine in the Western Pacific (2011-2020), 7-8 May 2012, Hong Kong SAR, China

- WHO Expert for The second WHO consultation on quality control of herbal medicines Hong Kong SAR, China, 17-

19 November 2014; 4-6 September 2017

- Organizing committee member for Traditional & Alternative Medicine 2016, Amsterdam, Netherlands, September

14-16, 2016

- Organizing committee Chairman for Pong Ding Yueng International Symposium on Chinese Medicine, Hong Kong,

1-3 December 2017

- Standing member of Hong Kong Registered Chinese Medicine Practitioner Association.

- Editors and reviewers for over sixty international journals in Chinese medicine, integrated medicine, complementary

and alternative medicine, as well as biomedicine etc.

WORK EXPERIENCE

2014 - Present: Associate Professor, Associate Director (Education), School of Chinese Medicine,

The University of Hong Kong, Hong Kong; and Hong Kong Registered Chinese

Medicine Practitioner

2011 - 2014: Associate Professor, Assistant Director (Education), School of Chinese Medicine,



2010 - 2011: Assistant Professor, Assistant Director (Education), School of Chinese Medicine,



2004 - 2010: Assistant Professor, Bachelor of Chinese Medicine (BChinMed in full- time) Programme Co-Ordinator,

School of Chinese Medicine, The University of Hong Kong, Hong Kong; and Hong Kong Registered

Chinese Medicine Practitioner

2002 - 2004: Chinese Medicine Assistant Professor, School of Chinese Medicine, The University of Hong Kong,

Hong Kong; and Limited Registered Chinese Medicine Practitioner in Hong Kong

2000 - 2002: CM Assistant Professor, Division of Chinese Medicine, SPACE, The University of Hong Kong, Hong

Kong; and Limited Registered Chinese Medicine Practitioner in Hong Kong.

1997 - 1999: Post Doctoral research fellow, Department of Laboratory Technology and Department of Medicine II,

Hokkaido University School of Medicine, Japan

1991 - 1993: Visiting Scientist, Department of Pharmacology, Faculty of Pharmacy, Meijio University, Japan

1987 - 1991: Lecturer, Department of Chinese Materia Medica, Yunnan College of Traditional Chinese Medicine,

3

China

1983 – 1985: Physician, Departments of Infection, Internal Medicine and Chinese Medicine, Dehong People’s

Hospital, Yunnan, China.

RESEARCH INTEREST AND ACHIEVEMENT

Dr Yibin Feng is currently an Associate Professor, Associate Director (education) in School of Chinese Medicine, the

University of Hong Kong. Dr. Feng awarded Bachelor degree in Chinese Medicine from Yunnan University of Chinese

medicine in China. He awarded his PhD degree in molecular medicine from Hokkaido University School of Medicine in

Japan. He finished postdoctoral research in molecular pharmacology, Hokkaido University in 1999. In the past years, Dr.

Feng got various scholarships and research funds from Chinese Government, Japanese Government, Sumitomo social

welfare consortium, FUJISAWA Pharmaceutical Limited Incorporation and TSUMURA KAMPO Pharmaceutical

Limited Incorporation etc. His major research areas and research topics are Standardization and quality control of Chinese

Medicines, Pharmacological screening and safety evaluation of Chinese Medicines; and Pharmacological action and its

mechanism of Chinese Medicines as well Chinese medicine education. As a PhD supervisor and principal investigator,

his research was supported by grants from the Research Council of The University of Hong Kong, The Research Grant

Committee (RGC) of Hong Kong, Pong Ding Yueng Endowment Fund for Education & Research in Chinese-Western

Medicine, Wong’s Donation for molecular cancer research in Chinese medicines, the Gaia Family Trust, Hong Kong

Government-Matching funding, Hong Kong Hospital Authority’s funding for Chinese Medicine, Teaching development

grant of the University of Hong Kong, and various industry contract research funding etc. As PI, awarded various grants

over 13 million HK$ from 2004-2017. As Co-I，awarded over 17 million HK$ from 2004-2017.

Being an expert in the study of Chinese Materia Medica, Pharmacology and Toxicology of Chinese medicines, Dr. Feng’s

research is focused on clinical study and experimental study for cancer, diabetes, hepatic and renal diseases by using

recently developed techniques in OMICS, pharmacology and immunology. He also commits to do substitute research for

some endangered species used in Chinese Medicine and Chinese medicine education. He has published over 360

publications in English, Japanese and Chinese in these areas. All these publications can be categorized to be top 5 journals

and quality one journals in his research field of Chinese medicine, Ethnopharmacology, alternative and complementary

Medicine. His research outputs have great impact on academic field, for example, his paper "Berberine and Coptidis

Rhizoma as novel antineoplastic agents: A review of traditional use and biomedical investigations" published in Journal

of Ethnopharmacology has been ranked No.1 in total 25 of the most cited articles published since 2009(visiting the

Journal web on September 28, 2014), open a new hot topic in the world and make his research always stand on top level

in this field of international arena. His research on coptis and bear bile also got great attention in academia and society,

for example, various media in Hong Kong, Mainland China, Taiwan and Oversea in 2008 have reported this research,

and at an international conference in London in August 2010, he was invited by BBC studio for interview, he was reported

by HKU bulletin in June 2013 about his research story in bear bile and one of his paper published in Journal of

Ethnobiology and Ethnomedicine (Bear bile: dilemma of traditional medicinal use and animal protection) in 2009 was

identified as highly accessed paper over 30000 accesses by November 23, 2017 on the journal website, etc.. In addition

to publish papers in my research area in journals of Chinese medicine and integrative medicine, I also published high

impact factor papers on Chinese herbal medicine in other reputable journals (Q1 journals in related categories), such as

British journal of Pharmacology (IF5.2), PLOS ONE (IF4.6), Molecular cancer (IF 5.30), Biochimica et Biophysica Acta

(BBA) - Molecular Basis of Disease (IF5.089), BBA-Molecular Cell Research (IF 5.297), BBA- Gene Regulatory

Mechanisms (IF5.440), Oncotarget (6.395), Cell death and Disease (IF5.5), BBA - Molecular and Cell Biology of Lipids,

(IF 5.55), Science Supplement (IF31), autophagy (IF11.5) and Theranostics (IF 8.85) etc.

TEACHING SUBJECTS

He has taught subjects such as Chinese Materia Medica, Pharmacology of Chinese Medicines, Toxicology of Chinese

Medicines, Chinese Internal Medicine and Pharmacology. Recently, he is responsible for teaching Chinese Materia

Medica, Pharmacology and toxicology of Chinese medicines, Oncology of Chinese Medicines and research methodology in Chinese medicine.

4

CLINICAL SERVICES Cancer, diabetes, obesity, liver diseases and renal diseases etc.

ACADEMIC INTERNATIONAL PROFESSIONAL SERVICE

Highly active in international communities of Chinese Medicine, Ethnopharmacology, complementary and alternative

medicine as well as life science, serving as editors or reviewers for the following international journals:

Editorial Board Members (over ten journals): (1) Evidence-Based Complementary and Alternative Medicine (eCAM)

(2) Integrative Cancer Therapy (3) Chinese Medicine (4) World Journal of Translational Medicine (5) Journal of

Bioequivalence & Bioavailability (6) ISRN Hepatology (7) Open Journal of Apoptosis (8) UC Alternative Medicine (9)

International Journal of Cancer & Diagnosis (IJCRD) etc.

Reviewers (over fifty journals): Evidence-Based Complementary and Alternative Medicine (IF 4.774), Chinese Journal

of Integrative Medicine (IF 1.059), Journal of Alternative and Complementary Medicine (IF1.464), Molecular and

Cellular Biochemistry (IF1.896), Regulatory Peptides (IF2.160), BMC Complementary and Alternative Medicine (BMC

CAM, IF 2.224), Molecules (IF 2.386), International Journal of Molecular Sciences (IF 2.464), Cell proliferation (IF

2.521), Journal of Agricultural and Food Chemistry (IF2.816), BioMed Research International (2.88), Chinese Medicine

(IF2,343), Planta Medica (IF 2.339), Phytomedicine (IF3.126), Journal of Ethnopharmacology (IF3.04), Bioorganic &

Medicinal Chemistry (IF3.07), Tumor Biology (IF3.61), Food and chemical toxicology (IF 3.68), BSP Current Medicinal

Chemistry (CMC, IF4.86), Expert Opinion On Therapeutic Patents (IF4.297), Expert Opinion on Therapeutic Targets

(IF5.139), Science Report (IF 5.578), BBA-Molecular Cell Research (IF 5.538) and Oncotarget (IF6.627) etc..

SELECTED PUBLICATIONS (*CORRESPONDING AUTHOR)

1. Wang N, Tan HY, Li S, Feng Y*. Atg9b Deficiency Suppresses Autophagy and Potentiates Endoplasmic

Reticulum Stress-Associated Hepatocyte Apoptosis in Hepatocarcinogenesis. Theranostics. 2017 Jun

2;7(8):2325-2338. doi: 10.7150/thno.18225. eCollection 2017. (IF = 8.854, 5-year IF).

2. Cheng Y, Feng Y, Xia Z, Li X, Rong J*. <omega>-Alkynyl arachidonic acid promotes anti-inflammatory

macrophage M2 polarization against acute myocardial infarction via regulating the cross-talk between PKM2,

HIF-1<alpha> and iNOS. BBA - Molecular and Cell Biology of Lipids, 2017 Dec;1862(12):1595-1605. doi:

10.1016/j.bbalip.2017.09.009. Epub 2017 Sep 28.

3. Hung J, Cao S, Tang H, He Y, Feng Y, Wang K, Zhang QS. Molecular targets and associated potential pathways

of Danlu capsules in hyperplasia of mammary glands based on systems pharmacology. Evidence-Based

Complementary and Alternative Medicine 2017, (IF1.931, 5-year IF2.014. Ever ranking No.1 with IF 4.774 in

Category of Integrative & Complementary Medicine in 2012).

4. Hong M, Li S, Tan HY, Cheung F, Wang N, Huang J, Feng Y*. A network-based pharmacology study of the

potential hepatotoxicity of traditional hepatoprotective Chinese herbal medicines. Molecules 2017, 22, 632;

doi:10.3390/molecules22040632 (IF 2.465, 5-year IF 2.749).

5. Hong M, Li S, Wang N, Tan HY, Cheung F, Feng Y*. A Biomedical Investigation on the Hepatoprotective Effect

of Radix Salviae Miltiorrhizae and Network pharmacology-based Prediction of the Active compounds and

Molecular Targets. International Journal of Molecular Sciences 2017, accepted for publication. (IF 3.257, 5-Year

IF 3.213).

6. Lan J, Wang N, Huang L, Liu Y, Ma X, Lou H, Chen C, Feng Y*, Pan W. Design and synthesis of novel

tetrandrine derivatives as potential anti-tumor agents against human hepatocellular carcinoma. European Journal

of Medicinal Chemistry. 2017 Feb 15;127:554-566. doi:10.1016/j.ejmech.2017.01.008. (IF 3.902, 5-year IF

3.982).

7. Tan HY, Wang NM, Tsao SW, Che CM, Yuen MF, Feng Y*. IRE1α Inhibition by Natural Compound Genipin

on Tumour Associated Macrophages Reduces Growth of Hepatocellular Carcinoma. Oncotarget. 2016 May 30. doi: 10.18632/oncotarget.9696. [Epub ahead of print] (IF 6.359, 5-year IF 6.368)

8. Feng Y*, Yuen MF, Xu Q, Wan XY, Wang DQ. Herbal medicine new exploration in hepatology. Evidence-Based

5

Complementary and Alternative Medicine. 2016; Editorial. 2016:3056438. doi: 10.1155/2016/3056438. Epub

2016 Jul 20. (IF 1.931, 5-year IF 2.014. Ever ranking No.1 with IF 4.774 in Category of Integrative &

Complementary Medicine in 2012)

9. Tan HY, Wang N, Man K, Tsao SW, Che CM, Feng Y*. Autophagy-induced RelB/p52 activation mediates tumor

associated macrophage repolarisation and suppression of hepatocellular carcinoma by natural compound baicalin.

Cell Death and Disease 2015; 6, e; doi:10.1038/cddis.2015.271 (Nature group, IF 5.378, 5years IF 6.03).

10. Li H, Wang X, Liu Y, Pan D, Wang Y, Yang N, Xiang L, Cai X, Feng Y*. Hepatoprotection and hepatotoxicity

of Heshouwu, a Chinese medicinal herb: context of the paradoxical effect. Food and Chemical Toxicology, 2016

Jul 30. pii: S0278-6915(16)30264-2. doi: 10.1016/j.fct.2016.07.035. [Epub ahead of print] (IF 3.584 and the 5-

Year IF 3.440).

11. Tan HY, Wang N, Takahashi M, Feng YG, Li HY, Feng Y*. New Natural Pigment Fraction Isolated from Saw

Palmetto: Potential for adjuvant therapy of Hepatocellular Carcinoma. International Journal of Molecular

Sciences, 2016 Aug 5; 17(8). pii: E1277. doi: 10.3390/ijms17081277. (IF 3.257, and the 5-Year Impact Factor

is 3.213).

12. Chan KW, Ip TP, Kwong AS, Lui SL, Chan GC, Cowling BJ, Yiu WH, Wong DW, Liu Y, Feng Y, Tan KC, Chan

LY, Leung JC, Lai KN, Tang SC. Semi-individualized Chinese Medicine Treatment as an Adjuvant Management

for Diabetic Nephropathy – A pilot add-on, randomised, controlled, multi-centre, open-label pragmatic clinical

trial. BMJ Open，2016 Aug 5;6(8):e010741. doi: 10.1136/bmjopen-2015-010741 (IF 2.562).

13. Hong M, Tan HY, Li S, Cheung F, Wang N, Nagamatsu T, Feng Y*. Cancer stem cells: the potential targets of

Chinese medicines and their active compounds. International Journal of Molecular Sciences, 2016 Jun 7;17(6).

pii: E893. doi: 10.3390/ijms17060893. Review. (IF3.257, and the 5-Year Impact Factor is 3.213).

14. Wang N, Xu Q, Tan HY, Hong M, Li S, Yuen MF, Feng Y*. Berberine inhibits fibrogenesis in a rat model of

liver fibrosis and in hepatic stellate cells. Evidence-Based Complementary and Alternative Medicine.

2016:8762345. doi: 10.1155/2016/8762345. Epub 2016 Apr 30. (IF1.931, 5-year IF2.014. Ever ranking No.1

with IF 4.774 in Category of Integrative & Complementary Medicine in 2012)

15. Tan HY, Wang N, Li S, Hong M, Wang X, Feng Y*. The reactive oxygen species in macrophage polarization:

reflecting its dual role in progression and treatment of human diseases. Oxidative Medicine and Cellular

Longevity. 2016; 2016:2795090. doi: 10.1155/2016/2795090. Epub 2016 Apr 6. Review. (IF 4.492, 5-year IF

4.667)

16. Wang X, Wang N, Li H, Liu M, Cao F, Yu X, Zhang J, Tan Y, Xiang L, Feng Y*. Up-Regulation of PAI-1 and

Down-Regulation of uPA Are Involved in Suppression of Invasiveness and Motility of Hepatocellular Carcinoma

Cells by a Natural Compound Berberine. International Journal of Molecular Science. 2016 Apr 16;17(4). pii:

E577. doi: 10.3390/ijms17040577. (IF3.257, and the 5-Year IF 3.213)

17. Li S, Tan HY, Wang N, Hong M, Li L, Cheung F, Feng Y*. Substitutes for bear bile for the treatment of liver

diseases: research progress and future perspective. Evidence-Based Complementary and Alternative Medicine.

2016:4305074. doi: 10.1155/2016/4305074. Epub 2016 Mar 21. Review. (IF1.931, 5-year IF2.014. Ever ranking

No.1 with IF 4.774 in Category of Integrative & Complementary Medicine in 2012)

18. Lam P, Cheung F, Tan HY, Wang N, Yuen MF, Feng Y*. Hepatoprotective effect of Chinese medicinal herbs: a

review with focus on its anti-inflammatory and anti-oxidative activities. International Journal of Molecular

Science. 2016 Mar 29;17(4). pii: E465. doi: 10.3390/ijms17040465. Review. (IF3.257, 5-Year IF 3.213)

19. Tan HY, San-Marina S, Wang N, Hong M, Li S, Li L, Cheung F, Wen XY, Feng Y*. Preclinical models for

investigation of herbal medicines in liver diseases: update and perspective. Evidence-Based Complementary and

Alternative Medicine. 2016; 2016:4750163. doi: 10.1155/2016/4750163. Epub 2016 Jan 28. Review. (IF1.931,

5-year IF2.014. Ever ranking No.1 with IF 4.774 in Category of Integrative & Complementary Medicine in 2012)

20. Li H, Cao S, Wang X*, Zuo Q, Chen P, Liu Y, Liu M, Feng Y*. Quality Evaluation of Heshouwu, a Taoist

Medicine in Wudang, China. Experimental and Therapeutic Medicine, 2016 Oct;12(4):2317-2323.

21. Liu JY, Chen XX, Tang SC, Sze SC, Feng Y, Lee KF, Zhang KY*. Chinese medicines in the treatment of

experimental diabetic nephropathy. Chinese Medicine. 2016 Feb 24;11:6. doi: 10.1186/s13020-016-0075-z.

(IF2.234)

22. Klionsky DJ*,…Feng Y, …et al. Guidelines for the use and interpretation of assays for monitoring autophagy

(3rd edition). Autophagy. 2016 Jan 2; 12(1):1-222. (IF 11.753, and the 5-Year Impact Factor is 11.958). 23. Wang N, Tan HY, Li L, Yuen MF, Feng Y*. Berberine and Coptidis Rhizoma as potential anticancer agents:

Recent updates and future perspectives. J Ethnopharmacol. 2015 Dec 24;176:35-48. doi:

6

10.1016/j.jep.2015.10.028. Epub 2015 Oct 19. Review.

24. Wang L, Wang N, Tan H, Zhang Y, Feng Y*. Protective Effect of a Chinese Medicine Formula He-Ying-Qing-

Re Formula on Diabetic Retinopathy. Journal of Ethnopharmacology. 2015 Jul 1;169:295-304. (IF 3.04, 5 year

IF 3.728, 1/22, Q1, No.1 in Category of Integrative & Complementary Medicine)

25. Wang N, Zhu M, Wang X, Tan HY, Tsao SW, Feng Y*. Berberine-induced tumor suppressor p53 up-regulation

gets involved in the regulatory network of MIR-23a in hepatocellular carcinoma. Biochim Biophys Acta (BBA)

- Gene Regulatory Mechanisms. 2014 Sep;1839(9):849-57. [IF 6.332].

26. Tsang CM, Cheung KC, Cheung YC, Man K, Lui VW, Tsao SW, Feng Y*. Berberine suppresses Id-1 expression

and inhibits the growth and development of lung metastases in hepatocellular carcinoma. Biochimica et

Biophysica Acta (BBA) -Molecular Basis of Disease 2015 Mar;1852(3):541-51. (IF 5.089, 5 year IF 5.13, Q1 in

Molecular medicine).

27. Xu Q, Feng Y, Duez P, Hendry BM, Hylands PJ. The hunt for anti-fibrotic and pro-fibrotic botanicals. The Art

and Science of Traditional Medicine Part 1: TCM Today – A Case for Integration, Science 2014;346 (6216 Suppl),

S19-S20. (IF 31.477, 5 year IF 34.463, 2/55, Q1, No.2 in Category of Multidisciplinary Sciences)

28. Wang N, Feng Y*, Zhu M, Siu FM, Ng KM, Che CM*. A Novel Mechanism of XIAP Degradation Induced by

Timosaponin AIII in Hepatocellular Carcinoma. Biochimica et Biophysica Acta (BBA) - Molecular Cell

Research 2013 Jul 29;1833(12):2890-2899. doi: 10.1016/j.bbamcr.2013.07.018. (IF 5.38, 5 years IF 4.814)

29. Cheung F, Wang XB, Wang N, Yuen MF, Ziea Eric TC, Tong Y, Wong VT, Feng Y*. Chinese medicines as an

adjuvant therapy for unresectable hepatocellular carcinoma during transarterial chemoembolization: a meta-

analysis of randomized controlled trials. Evidence-Based Complementary and Alternative Medicine

2013:487919. doi: 10.1155/2013/487919. Epub 2013 Jul 17. (IF4.774)

30. Wang N, Zhu M, Tsao SW, Man K, Zhang ZJ, Feng Y*. MiR-23a-Mediated Inhibition of Topoisomerase 1

Expression Potentiates Cell Response to Etoposide in Human Hepatocellular Carcinoma. Molecular Cancer 2013

Oct 8; 12(1):119. (IF 5.40)

31. Wang N, Pan W, Zhu M, Zhanf M, Hao X, Liang G, Feng Y*. Fangchinoline induces autophagic cell death via

p53/sestrin2/AMPK signaling in human hepatocellular carcinoma cells. British Journal of Pharmacology.

2011;164(2b):731-742. (IF 5.209, total no. of citations since publication is 22 by Google scholar).

32. Wang N, Zhu M, Tsao SW, Man K, Zhang ZJ, Feng Y*. Up-regulation of TIMP-1 by Genipin Inhibits MMP-2

activities and Suppresses the Metastatic Potential of Human Hepatocellular Carcinoma. PLOS ONE,

2012;7(9):e46318. doi: 10.1371/ journal.pone.0046318. (IF 4.092, 5 year IF 4.532).

33. Wang N, Feng Y*, Tan HY, Cheung F, Hong M, Lao L, Nagamatsu T. Inhibition of Eukaryotic Elongation

Factor-2 Confers to Tumor Suppression by a Herbal Formulation Huanglian-Jiedu Decoction in Human

Hepatocellular Carcinoma. Journal of Ethnopharmacology, 2015 Feb 17. pii: S0378-8741(15)00103-8. doi:

10.1016/j.jep.2015.02.025. (IF 3.04, 5 year IF 3.728, 1/22, Q1, No.1 in Category of Integrative &

Complementary Medicine)

34. Li H, Cao S, Wang X*, Zuo Q, Chen P, Liu Y, Liu M, Feng Y*. Quality Evaluation of Heshouwu, a Wudang

Taoist Medicine in China. Exp. Ther. Med., 2015 Accepted for publication.

35. Klionsky DJ*,…Feng Y, …et al. Guidelines for the Use and Interpretation of Assays for Monitoring Autophagy

(2nd edition). Autophagy 2015, accepted for publication (IF11.753).

36. Wang X*, Xiang L, Li H, Chen P, Feng Y, Zhang J, Yang N, Li F, Wang Y, Zhang Q, Li F, Cao F. The Role of

HMGB1 Signaling Pathway in the Carcinogenesis and Progress of Hepatocellular Carcinoma: a Review.

International Journal of Molecular Science 2015 Sep 17;16(9):22527-40. doi: 10.3390/ijms160922527. (IF2.862)

37. Wang N, Feng Y*. Elaborating the Role of Natural Products-Induced Autophagy in Cancer Treatment:

Achievements and Artifacts in State-of-Art. Biomed Res Int. 2015;2015:934207. doi: 10.1155/2015/934207.

Epub 2015 Mar 3. [IF 2.706, 5 year IF 2.750].

38. Wang N, Feng Y, Cheung F, Wang X, Zhang ZJ, Feng Y*. A Chinese Medicine Formula Gegen Qilian Decoction

Suppresses Expansion of Human Renal Carcinoma with Inhibition of Matrix Metalloproteinase-2. Integrated

Cancer therapy 2015 Jan;14(1):75-85. doi: 10.1177/1534735414550036. Epub 2014 Sep 15. (IF 2.354, 5 year IF

2.479).

39. Wang X, Wang N, Cheung F, Lao L, Li C, Feng Y*. Chinese medicines for prevention and treatment of human

hepatocellular carcinoma: Current progress on pharmacological actions and mechanisms. Journal Integrative Medicine. 2015; 13(3):142-64.

40. Wang X, Feng Y*, Wang N, Cheung F, Tan HY, Zhong S, Li C, Kobayashi S. Chinese Medicines Induce Cell

http://www.sciencedirect.com/science/article/pii/S0167488913002930



7

Death: The Molecular and Cellular Mechanisms for Cancer Therapy. Biomed Res Int. 2014;2014:530342. doi:

10.1155/2014/530342. Epub 2014 Oct 14. Review. [ IF 2.706, 5 year IF 2.750]

41. Xu B, Wang N, Pan W, Qiu J, Cao P, Zhu M, Feng Y*, Liang G*. Synthesis and anti-tumor activity evaluation

of Matijin-Su derivatives. Bioorg Chem. 2014 Jun 2;56C:34-40. doi: 10.1016/j.bioorg.2014.05.009. [Epub ahead

of print] [IF 2.141, 5 year IF 1.720]

42. Ouyang L, Zhang Q, Ruan X, Feng Y, Wang X*. Treatment effect of Bushen Huayu extract on postmenopausal

osteoporosis in vivo. Exp. Ther. Med., 2014 Jun;7(6):1687-1690. Epub 2014 Apr 2. [IF1.268, 5 year IF]

43. Chen HY, Feng Y, Lao L*. Chinese integrative medicine: inclusion of a Chinese medicine programme in a

conventional medical institute. J. Integr. Med., 2014 May;12(3):187-90. doi: 10.1016/S2095-4964(14)60027-3.

44. Feng Y*, Wang N, Hong M. Cancer Chemotherapy: Time for New Solution. Chemotherapy 2014, 3:2.

http://dx.doi.org/10.4172/2167-7700.1000130.

45. Tan HY, Wang N, Tsao SW, Zhang ZJ, Feng Y*.Suppression of Vascular Endothelial Growth Factor via

Inactivation of Eukaryotic Elongation Factor-2 by Alkaloids in Coptidis rhizoma in Hepatocellular Carcinoma.

Integrated Cancer therapy 2014 Sep;13(5):425-34. (IF 2.354, 5 year IF 2.479).


Achievements and Artifacts in State-of-Art. Biomed Res Int. Accepted for publication. [IF 2.706, 5-year IF

2.750].



Cancer therapy 2015 Jan;14(1):75-85. doi: 10.1177/1534735414550036. Epub 2014 Sep 15. (IF 2.354, 5-year

IF 2.479).


hepatocellular carcinoma: Current progress on pharmacological actions and mechanisms. J Integr Med. 2015;

13(?): 000-000. accepted January 27, 2015.

49. Wang X, Feng Y*, Wang N, Cheung F, Tan HY, Zhong S, Li C, Kobayashi S. Chinese Medicines Induce Cell

Death: The Molecular and Cellular Mechanisms for Cancer Therapy. Biomed Res Int. 2014;2014:530342. doi:

10.1155/2014/530342. Epub 2014 Oct 14. Review. [ IF 2.706, 5-year IF 2.750]

50. Wang N, Zhu M, Wang X, Tan HY, Tsao SW, Feng Y*. Berberine-induced tumor suppressor p53 up-regulation

gets involved in the regulatory network of MIR-23a in hepatocellular carcinoma. Biochim Biophys Acta. 2014

Jun 3. pii: S1874-9399(14)00141-2. doi: 10.1016/j.bbagrm.2014.05.027.

51. Xu B, Wang N, Pan W, Qiu J, Cao P, Zhu M, Feng Y*, Liang G*. Synthesis and anti-tumor activity evaluation

of Matijin-Su derivatives. Bioorg Chem. 2014 Jun 2;56C:34-40. doi: 10.1016/j.bioorg.2014.05.009. [Epub ahead

of print]


osteoporosis in vivo. Exp Ther Med. 2014 Jun;7(6):1687-1690. Epub 2014 Apr 2.


conventional medical institute. J Integr Med. 2014 May;12(3):187-90. doi: 10.1016/S2095-4964(14)60027-3.


http://dx.doi.org/10.4172/2167-7700.1000130.

55. Tsang CM, Cheung YC, Lui VW, Yip YL, Zhang G, Lin VW, Cheung K, Feng Y*, Tsao SW*. Berberine

suppresses tumorigenicity and growth of nasopharyngeal carcinoma cells by inhibiting STAT3 activation

induced by tumor associated fibroblasts. BMC Cancer. 2013 Dec 31; 13(1):619. doi: 10.1186/1471-2407-13-619.

56. Feng Y*, Wang N. The new generation of drug discovery and its analytical technologies. Editorial.

Bioequivalence & Bioavailability 2013,5:e42.doi:10.4172/ jbb.10000e42.

57. Tan HY, Wang N, Tsao SW, Zhang Z, Feng Y*. Suppression of Vascular Endothelial Growth Factor via

Inactivation of Eukaryotic Elongation Factor-2 by Alkaloids in Coptidis rhizoma in Hepatocellular Carcinoma.

Integrated Cancer therapy 2013 Dec 19. [Epub ahead of print].

58. Wang D, Wong HK, Feng Y, Zhang ZJ. Liquiritigenin exhibits antitumour action in pituitary adenoma cells via

Ras/ERKs and ROS-dependent mitochondrial signalling pathways. J Pharm Pharmacol. 2014 Mar;66(3):408-17.

doi: 10.1111/jphp.12170. Epub 2013 Nov 6.

59. Wang D, Wong HK, Feng Y, Zhang ZJ.18beta-Glycyrrhetinic acid induces apoptosis in pituitary adenoma cells via ROS/MAPKs-mediated pathway. J Neurooncol. 2014 Jan;116(2):221-30. doi: 10.1007/s11060-013-1292-2.

Epub 2013 Oct 27.

http://www-ncbi-nlm-nih-gov.eproxy1.lib.hku.hk/pubmed/24491032




8

60. Wang N, Zhu M, Tsao SW, Man K, Zhang Z, Feng Y*. MiR-23a-mediated inhibition of topoisomerase 1

expression potentiates cell response to etoposide in human hepatocellular carcinoma. Mol Cancer. 2013 Oct

8;12(1):119. doi: 10.1186/1476-4598-12-119.

61. Zhang Q, Li H, Wang S, Liu M, Feng Y, Wang X. Icariin protects rat cardiac H9c2 cells from apoptosis by

inhibiting endoplasmic reticulum stress. Int J Mol Sci. 2013 Aug 30;14(9):17845-60. doi:

10.3390/ijms140917845.


Timosaponin AIII in Hepatocellular Carcinoma. Biochimica et Biophysica Acta (BBA) - Molecular Cell

Research 2013; 1833(12):2890-2899. doi: 10.1016/j.bbamcr.2013.07.018.



analysis of randomized controlled trials. Evidence-Based Complementary and Alternative Medicine

2013:487919. doi: 10.1155/2013/487919.

64. Wang D, Wong HK, Feng Y, Zhang ZJ. Paeoniflorin, a natural neuroprotective agent, modulates multiple anti-

apoptotic and pro-apoptotic pathways in differentiated PC12 cells. Cell Mol Neurobiol. 2013 May;33(4):521-9.

doi: 10.1007/s10571-013-9914-y. Epub 2013 Feb 24.

65. Wang N, Feng Y*, Zhu M, Chow O, Wang XB, Su W, Tong Yao. A Comparative Study on the Hepatoprotective

Action of Coptidis Rhizoma Aqueous Extract and Bear Bile on Carbon Tetrachloride induced Liver Fibrosis in

Rats. BMC Complement Altern Med. 2012;12(1):239.


activities and Suppresses the Metastatic Potential of Human Hepatocellular Carcinoma. PLoS One.

2012;7(9):e46318.

67. To CS, Liew C, Wang XB, Wang N, Feng Y*. Comparison of Components and Anti-Liver Cancer Activity in

vitro between Huanglian and Yunlian. Journal of Bioequivalence & Bioavailability 2012, 4: 086-090. doi:

10.4172/jbb.10000118.

68. Wang XB, Feng Y*, Wang N, Cheung F, Wong CW. Recent Progress on Anti-Liver Fibrosis Candidates in

Patents of Herbal Medicinal Products. Recent Pat Food Nutr Agric. 2012; 4:91-106.

69. Wang D, Wong HK, Zhang L, McAlonan GM, Wang XM, Sze SC, Feng YB, Zhang ZJ. Not only dopamine D(2)

receptors involved in Peony-Glycyrrhiza Decoction, an herbal preparation against antipsychotic-associated

hyperprolactinemia. Prog Neuropsychopharmacol Biol Psychiatry 2012; 39(2):332-8.

70. Wang XB, Feng Y*, Wang N, Cheung F, Wong CW. Recent Progress on Anti-Liver Fibrosis Candidates in

Patents of Herbal Medicinal Products. Recent Pat Food Nutr Agric. 2012 Aug 1;4(2):91-106.

71. Hirasawa Y, Nishiyama T, Nagao T, Feng Y, Nagamatsu T. Involvement of Protein Kinase C in Reduction of

Aggregated Protein and Phosphorylation of CREB in Glomeruli. Experimental Animals 2012;61(2):119-24

72. Cheung F, Feng Y*, Wang N, Yuen MF, Tong Y, Wong VT. Effectiveness of Chinese herbal medicine in treating

liver fibrosis: a systematic review and meta-analysis of randomized controlled trials. Chin Med. 2012 Feb 29;

7(1):5.

73. Hirasawa Y, Sakai T, Ito M, Yoshimura H, Feng Y, Nagamatsu T. Advanced-glycation-end-product-cholesterol-

aggregated-protein accelerates the proliferation of mesangial cells mediated by transforming-growth-factor-beta

1 receptors and the ERK-MAPK pathway. European Journal of Pharmacology 2011 Dec 15;672(1-3):159-68.

74. Feng Y*, Wang N, Ye X, Li H, Feng Y, Cheung F, Nagamatsu T. Hepatoprotective effect and its possible

mechanism of Coptidis rhizoma aqueous extract on carbon tetrachloride-induced chronic liver hepatotoxicity in

rats. Journal of Ethnopharmacology 2011 Dec 8;138(3):683-90. doi: 10.1016/j.jep.2011.09.032.

75. Wang N, Pan W, Zhu M, Zhanf M, Hao X, Liang G*, Feng Y*. Fangchinoline induces autophagic cell death via

p53/sestrin2/AMPK signaling in human hepatocellular carcinoma cells. British Journal of Pharmacology

2011;164(2b):731-742.

76. Zhang ZJ, Tan QR, Tong Y, Wang XY, Wang HH, Ho LM, Wong HK, Feng Y, Wang D, Ng R, McAlonan GM,

Wang CY, Wong VT. An epidemiological study of concomitant use of chinese medicine and antipsychotics in

schizophrenic patients: implication for herb-drug interaction. PLoS One 2011;6(2):e17239.

77. Feng Y*, Wang N, Zhu M, Feng YG, Li HY, Tsao SW. Recent progress on anticancer candidates in herbal

medicinal products. Recent patent in Food, Nutrition & Agriculture. 2011, 3(1):30-48. 78. Wang N, Feng Y*, Xie TN, Su W, Zhu M, Chow O, Zhang Y, Ng KM, Leung CH, Tong Y. Chemical and

biological analysis of active free and conjugated bile acids in animal bile by using HPLC-ELSD and MTT








http://www.ncbi.nlm.nih.gov/pubmed/22594662







9

methods. Experimental and Therapeutic Medicine 2011, 2: 125-130.

79. Zhu M, Wang N, Tsao S, Yuen M, Feng YG, Wan Thomas SK, Man K, Feng Y*. Up-regulation of microRNAs,

miR21 and miR23a, in human liver cancer cells treated with Coptidis Rhizome aqueous extract. Experimental

and Therapeutic Medicine 2011, 2: 27-32.

80. Ng ZB, Xiao L, Feng Y, Tong Y, Wong JH, Yao RM, Li L, Mo FZ, Xiao Y, Shaw PC, Li ZM, Sze CW, Zhang Y.

Dendrobium candidum extract increases the expression of aquaporin 5 in labial glands from patients with

Sjögren’s Syndrome. Phytomedicine 2011;18(2-3):194-8.

81. Wang N, Feng Y*, Lau EP, Tsang C, Ching Y, Man K, Tong Y, Nagamatsu T, Su W, Tsao S. F-actin reorganization

and inactivation of rho signaling pathway involved in the inhibitory effect of Coptidis Rhizoma on hepatoma

cell migration. Integrate Cancer Therapy 2010, 9(4):354-64.

82. Wang N, Feng Y*, Zhu M, Tsang CM, Man K, Tong Y, Tsao SW. Berberine induces autophagic cell death and

mitochondrial apoptosis in liver cancer cells: the cellular mechanism. Journal of cellular biochemistry 2010,

111(6):1426-36.

83. Feng Y*, Siu KY, Ye X, Wang N, Yuen MF, Leung CH, Tong Y, Kobayashi S. Hepatoprotective effects of

berberine on carbon tetrachloride- induced acute liver hepatotoxicity in rats. Chinese Medicine 2010, 5:33 (1-6).

84. Lin X, Sze CW, Tong Y, Zhang Z, Feng Y, Chen JP, Ng TB, Lin X, Shaw PC, Zhang Y. Protective Effect of

Dendrobium officinale Polysaccharides on Experimental Sjogren's Syndrome. Journal of Complementary and

Integrative Medicine 2010, 7(1): DOI: 10.2202/1553-3840.1342.

85. Feng Y, Cheung KF, Wang N, Liu P, Nagamatsu T, Tong Y*. Chinese medicines as a resource for liver fibrosis

treatment. Chinese Medicine 2009; 4(1):16(1-11).

86. Tang J, Feng Y*, Tsao S, Wang N, Curtain R, Wang Y. Berberine and Coptidis Rhizoma as novel antineoplastic

agents: A review of traditional use and biomedical investigations. Journal of Ethnopharmacology 2009; 126:5-

17.

87. Tsang CM+, Lau Echo PW+, Di K, Cheung PY, Hau PM, Ching YP, Wong YW, Cheung Annie LM, Wan Thomas

SK, Tong Y, Tsao SW* and Feng Y*. Berberine inhibits RhoGTPases and cell migration at low doses but induces

G2 arrest and apoptosis at high doses in human cancer cells. International Journal of Molecular Medicine 2009;

24:131-138.

88. Ye XS, Feng Y*, Tong Y, Ng KM, Tsao SW, Lau George KK, Sze CW, Zhang YB, Tang J, Shen JG, Kobayashi

S. Hepatoprotective effects of Coptidis Rhizoma aqueous extract on carbon tetrachloride-induced acute liver

hepatotoxicity in rats. Journal of Ethnopharmacology 2009; 124:130–136.

89. Feng Y*, Siu K, Wang N, Ng KM, Tsao SW, Nagamatsu T, Tong Y. Bear bile: dilemma of traditional medicinal

use and animal protection. Journal of Ethnobiology and Ethnomedicine 2009, 5:2 (1-9).

90. Wang N, Wang Y, Li P, Peng W, Xie T, Feng Y, Su W. The Bioavaliability of Hepatoprotective Flavoniods in

Hypericum Japonicum Extract. Journal of Bioanalysis & Biomedicine. 2009 1(1):33-8.

91. Hirasawa Y, Matsui Y, Ohtsu S, Yamane K, Toyoshi T, Kyuki K, Sakai T, Feng Y, Nagamatsu T*. Involvement

of hyperglycemia in deposition of aggregated protein in glomeruli of diabetic mice. European Journal of

Pharmacology 2008, 601(1-3):129-35.

92. Tang J, Feng Y*, Tong Y, Yap M, Man YK*. A distinct new microscopic feature for identification of the crude

drug of Radix Angelicae Pubescentis. Journal of Chinese Medicinal Materials 2008, 31(12):1796-1802.

93. Tang J, Feng Y, Tong Y, Jia RR, SY LK, Man RK. Identification of mucilage cavity as a significant microscopic

characteristic existing in phloem instead of pith of Radix et Rhizoma Rhei. Wuhan University Journal of Natural

Sciences 2008, 13(2): 239-246.

94. Sze SC, Song JX, Wong RN, Feng Y, Ng TB, Tong Y*, Zhang KY*. Application of SCAR (sequence

characterized amplified region) analysis to authenticate Lycium barbarum (wolfberry) and its adulterants.

Biotechnol Appl Biochem 2008, 51(Pt 1):15-21.

95. To YD, Feng Y*. Metabolic Syndrome treated by Chinese medicine and one case report. Hong Kong Chinese

Medical Journal. 2015, 10(2):54-58.

96. Wang LL, Wang N, Feng Y*, Zhang YJ*. Clinical and basic research advance of Traditional Chinese Medicines

on Diabetic Retinopathy. Journal of Traditional Chinese Ophthalmology, 2014, 24(3): 227-232.

97. Lam PY, Feng Y*. Relationship exploration of diabetic combined with colorectal cancer and one case treated by

granular powder of Chinese medicines. Hong Kong Chinese Medical Journal. 2014, 9(1):31-36. Hong Kong.




10

98. Chan L, Cheung F, Feng Y*. Advanced progress on prevent and treatment of liver cancer by Chinese medicines.

Hong Kong Chinese Medical Journal. 2013, 8(2):80-86. Hong Kong.

99. Lam PY，Feng Y*. Relationship exploration of diabetic combined with cholangiocarcinoma and one case report.

Hong Kong Chinese Medical Journal. 2013, 8(1):26-29. Hong Kong.

100. Lam SS，Feng Y*. The effects of Xiong sha liu jun tan and ge gen qin lian tan in colon cancer treatment.

Hong Kong Chinese Medical Journal 2011, 6(3):35-38. Hong Kong. (In Chinese).

101. Lam SS and Feng Y*. The effects and mechanism of Chinese herbs in the category of heat-clearing

herbs. Hong Kong Chinese Medical Journal. 2009, 4(1):97-105. Hong Kong. (In Chinese).

102. Feng Y*, Luo Weiquan, Zhu Shiqin. Explore new clinical application of Huanglian and corresponding

compound prescriptions from their traditional use. China Journal of Chinese Materia Medica. 2008,

33(10):1221-1225. (In Chinese).

103. Feng Y*, Tang Yao. From modern research of Chinese medicines to view basic characteristics of

Chinese medicine. Hong Kong Chinese Medical Journal. 2008; 3(1): 17-21. Hong Kong. (In Chinese).

104. Feng Y*, Xingshen Ye, Yao Tong. Set up surveillance system for herbs adverse action, exert the role of

Chinese Medicine on Prevention and treatment of drug abuse in Hong Kong. Chinese Journal of

Drug Abuse Prevention and Treatment. 2007; 13(4):220-223. Beijing. (In Chinese).

105. Feng Y*, Chan KS. Basic status and comments on adverse reaction and poisoning of Chinese medicines

in national and international databases. Hong Kong Chinese Medical Journal. 2007; 2(1): 27-33.

Hong Kong. (In Chinese).

106. Feng Y*, Tong Y, Lau PW. Research methodology of TCM Formulas. Hong Kong Chinese Medical

Journal, 2006; 1(2):64-67. Hong Kong. (In Chinese).

107. Feng Y*, Tong Y, Tang J, Zhu SQ. On Standardization of Chinese Materia Medica in Hong Kong.

Shanghai Journal of Traditional Chinese medicine, 2005, 39(10):3-4. Shanghai. (In Chinese).

108. Feng Y*, Luo WQ. Multiple Assessment Methods in Education of Chinese Medicine. The first

international conference on enhancing teaching and learning through Assessment, 2005; pp.134-135. Hong

Kong.

109. Feng Y*. Ideas and practice for teaching of Chinese Materia Medica. Journal of TCM Education. 2004;

2(8):38-40.Beijing. (In Chinese).

110. Feng Y*. Modern research of Chinese Medicine and its future. Asia Pacific Biotech, 2004; 2(1):48-52.

Singapore. (In Chinese).

111. Low WQ, Feng Y. Clinical study of Chinese herb prescriptions on adenoma of large intestine and its

cancer. Journal of Traditional Chinese Medicine, 2004; 45:78-79. Beijing. (In Chinese).

112. Feng Y, Nagamatu T, Suzuki Y*, Kawata T, Feng YG, Kobayashi S and Koike T. Pharmacological

studies of diuretic TCM formulations: its application and evaluation of Pharmacological screening.

Journal of Traditional Medicines, 2000; 17(3):122-130. Toyama, Japan. (In Japanese).

113. Tarao F, Morimoto M, Feng Y, Kobayashi S*. Effect of heat inactivation of serum samples on soluble

Fas measurement. Annul reports in Hokkaido University, 1999; pp.1-8. Sapporo, Japan. (In Japanese).

114. Kobayashi S*, Feng Y. Fas and Fas ligand in autoimmue diseases. Journal of Modern Medicine and

Medical Technology, 1998; 30(1):282-285. Tokyo, Japan. (In Japanese).

115. Feng Y*. Studies on Fas Ligand Expression in Patients with Systemic Lupus Erythematosus. Hokkaido

Journal of Medical Science, 1997; 72(4):443-455. Sapporo, Japan. (In Japanese).

116. Jodo S, kobayashi S*, kayagaki N, Ogura N, Feng Y, Amasaki Y, Fujisaku A, Azuma M, Yagita H,

Okumura K and Koike T. Serum levels of soluble Fas APO-1(CD95) and its molecular structure in

patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. Clin Exp Immunol,

1997; 107:89-95. New York, USA.

117. Feng Y*, Nagamura T, Suzuki Y, Kawada T, Koike T. The diuretic effects of Chinese medicine

prescription on normal rats and various pathological models. Journal of Traditional

Medicines,1996;13(4):484-485. Toyama, Japan. (In Japanese).

118. Feng Y*. Ideas from “Golden Chamber” bring new therapy into Bechet’s syndrome. Journal of Chengdu College of Traditional Chinese Medicine. 1991; 14(1):19-20. Chengdu, China. (In Chinese).

119. Feng Y*. Clinical research of Chinese Medicines. Journal of Yunnan College of Traditional Chinese

11

Medicine.1987; 10(4):7-10. Kunming, China. (In Chinese).

BOOKS AND CHAPTERS IN BOOKS (* CORRESPONDING AUTHOR) 1. Chen Chang-xun (Editor in Chief). Editorial board: Cao HY, Chen LY, Chen YF, Fang XY, Feng Y, Gu WL, Gu Y,

Hua YQ, Huang LL, Nie Hong, Qu F, Shen YH, Solos L, Wang B, Wang J, Wang N, Wang XB, Wang YY, Xu HB,

Yu S, Zhang JX. Pharmacology of Chinese Materia Medica. National “Thirteenth Five-Year_Plan” Inovative

Textbooks for higher education in Chinese Medicine. China Press of Traditional Chinese Medicine. Beijing. Pp267

(in English).

2. Chen Dexing, Wen xiapin (Editor in Chief), Editorial board: Chen BZ, Chen DX, Du GL, Fan Y, Feng Y, Hu FL,

Hua HM, Jia P, Ni C, Nian L, Ruan SB, Wang F, Wang JN, Wen XP, Xin ZP, Xu XD, Yu Y, Yun XL. National

Textbook for Chinese Medicine Prescription. Qinghua University Press, 1th edition, 2013. Beijing, China. pp394 (in

Chinese).

3. Alan Worsley, Feng Y, Wang N, Ho Faith, Yu Edwin, Rose Mak. Use of Herbs in Chinese and Western Medicine.

Hong Kong Museum of Medical Sciences Society. 1th edition in Bilingual in Chinese and English, 2013. Hong Kong,

China. pp67 (in Bilingual).

4. Xie Mengzhou (Editor in Chief). Editorial board: Shang YQ, Yi W, Zhou J, Wu ZZ, Nie H, Shi LP, Tian SL, Feng Y,

Sun ZM, Li HT, Zhang B, Lin Y, Jin H, Zhou Y, Zhao XW, Guo T, Liang XW, Xie XJ, Tai X, Sun GX. National

Textbook for diet therapy. Zhong Guo Zhong Yi Yao Chu Ban She (China Chinese medicine and Chinese medicines

publisher), 2nd edition, 2013. Beijing, China. pp387. (in Chinese)

5. Feng YG, Wang N, Chueng F, Zhu M, Li H, Feng Y*. Molecular and Cellular Mechanism Studies on Anticancer

Effects of Chinese Medicines. Chapter in Biomedical Engineering, Trends, Research and Technologies (pp332-362).

ISBN 978-953-307-514-3. 2011, pp644. (in English).

6. Feng Y, Chen XM, Wang N and Shen JG*. Current Progress on Medicinal Plants and their Biological Properties in

Contemporary China (Around 20,000 words). Chapter in Recent Progress in Medicinal Plants Vol. 28:

Ethnomedicine: Source & Mechanism-II. Studium Press LLC, USA. 2010, pp491-546. (in English).

7. Tong Y* and Feng Y. Assessments in the Bachelor of Chinese Medicine (BChinMed) Programme. Chapter in The

assessment of the University of Hong Kong. 2009, pp51-58. Published by Institute of Medical and Health Sciences

Education, Li Ka Shing Faculty of Medicine, The University of Hong Kong. (in English).

8. Feng Y*, Editor-in-chief; editorial board: Liu KJ, Wang J, Shen JG, Zhang YB, Rong JH, Tong Y, Chan KS and

Wong Albert B. Basic and Clinical Toxicology of Chinese Medicines (around 460,000 words). Commercial Press

(HK) Ltd. 2009. (Chinese).

9. Yang GQ, Wu ZB, Zhang DN, Jin JM, Feng Y. A study on the prescriptions in “Herbal medicines in Yunnan”.

Published by Science and Technology of Yunnan Press,1993 (ISBN7-5416-0473- 9/R.86).pp.1-319. (in Chinese).

12

馮奕斌博士香港大學中醫藥學院副教授，副院長(教學)

聯絡方法

郵寄地址︰香港薄扶林沙宣道 10 號香港大學中醫藥學院

電話: (852) 2589 0482

傳真: (852) 2872 5476

電郵︰ [email protected]

口頭語言：普通話，英語，廣東話和日語

寫作語言：中文，英文和日文

專業領域：中藥學，中藥藥理學和中藥毒理學；肝腎病學,代謝性疾病和腫瘤學；中醫藥教育

學歷

醫學學士，研究生課程（中國，雲南中醫學院），醫學博士（日本，北海道大學醫學院）.

目前工作簡介

香港大學中醫藥學院副教授，副院長（教學），醫學博士, 博士生導師，長期活耀在中醫藥教育、臨床和研究

的第一線，2012 擔任第三屆國際藥膳食療及第三屆中國藥膳食療大會的大會執行主席，2013，2014 和 2018 年

擔任三屆國際現代化中醫藥學術會議聯席主席(ICMCM)，2017 年香港大學龐鼎元國際中醫藥研討會主席，兼

任香港中醫藥管理委員會中醫組中醫學位課程評審委員，香港醫院管理局中藥委員會委員，香港中醫藥管理委

員會中成藥註冊評審專家組專家，香港註冊中醫學會常務委員，也兼任國內多個大學或研究機構的客座教授，

如湖北省楚天講座教授，湖北醫藥學院神農講座教授，中國科學院和貴州省天然化學重點實驗室教授，國內多

個醫藥院校的客座教授等，定期被邀請作有關領域的學術講座。也曾任日本名城大學，日本北海道大學，沙特

國王阿卜杜拉斌健康科學大學和美國耶魯大學的客座研究員, 客座教授和訪問科學家。近年擔任 60 多家國際專

業雜誌的編委和評審員，如 Evidence-Based Complementary and Alternative Medicine (IF 4.774), Chinese Medicine

(IF2.343) 等的編委, Chinese Journal of Integrative Medicine (IF 1.059), Journal of Alternative and Complementary

Medicine (IF1.464), Molecular and Cellular Biochemistry (IF1.896), Regulatory Peptides (IF2.160), BMC

Complementary and Alternative Medicine (BMC CAM, IF 2.224), Molecules (IF 2.386), International Journal of

Molecular Sciences (IF 2.464), Cell proliferation (IF 2.521), Journal of Agricultural and Food Chemistry (IF2.816),

BioMed Research International (2.88), Planta Medica (IF 2.339), Phytomedicine (IF2.877), Journal of

Ethnopharmacology (IF3.04), Bioorganic & Medicinal Chemistry (IF3.07), Food and chemical toxicology (IF 3.68), BSP

Current Medicinal Chemistry (CMC, IF4.86), Science Report (IF 5.02), BBA-Molecular Cell Research (IF 5.538) and

Oncotarget (IF6.627)等的評審員等.

工作經歷

2014 - 至今：香港大學中醫藥學院副教授，副院長（教學），博士生和博士後導師，香港政府註冊中醫師

2011 - 2014：香港大學中醫藥學院副教授，助理院長（教學），博士生和博士後導師，香港政府註冊中醫師

2010 - 2011：香港大學中醫藥學院助理教授，助理院長（教學），博士生導師，香港政府註冊中醫師

2004 - 2009：香港大學中醫藥學院助理教授，學院全日制課程統籌主任，碩士研究生導師,博士生導師，香港政

府註冊中醫師

2002 - 2004：香港大學中醫藥學院中醫助理教授，碩士研究生導師，香港政府有限度註冊中醫師

mailto:[email protected]

13

2000 - 2002：香港大學專業進修學院中醫助理教授，香港政府有限度註冊中醫師

1997 - 1999：日本札幌市北海道大學醫學院博士後研究學者

1991 - 1993：日本名古屋市名城大學藥學院藥理學訪問科學家

1987 - 1991：中國雲南中醫學院中藥教研室講師

1983 - 1985：中國雲南省德宏州人民醫院醫師

科研方向與業績

專業方向為藥理學，中藥藥理學和中藥毒理學，尤其關注並主要從事中醫藥防治腫瘤和肝腎及糖尿病的基礎和

臨床研究，也專注於所研究領域的保健品、藥物研發以及發酵技術在中藥保健品中的應用，目前指導香港大學

研究助理教授 1名，博士後 2名，在讀博士生 6名，均為高額獎學金獲得者，另有 3名研究助理，兩名在研訪

問學者及兩名受訓國際學生。8 名受訓過的博士、博士後、訪問學者或高級訪問學者回國後，均獲聘為中國內

地著名大學的教授、副教授職位。

馮奕斌博士的研究興趣是中藥在惡性腫瘤，內分泌代謝性疾病和自身免疫性疾病中臨床應用規律的探討；

對中藥單方, 複方及其活性成分的藥理作用, 作用機制和安全性進行評價。曾獲中國政府，日本政府，日本北海

道政府，北海道大學，日本住友社會福祉財團，日本滕澤製藥股份有限公司和日本津村漢方製藥有限公司等的

獎學金和研究基金。近年獲得香港大學研究基金，香港大學教育發展研究基金，香港政府研究基金，香港政府

創新科技基金，黃氏基金，龐鼎元中西醫教學與研究基金，大地女神基金，香港政府配套基金，香港醫院管理

局中醫藥研究基金以及香港和內地企業合約研究基金等的支持，作為首席研究者，獲得超過 1.3 千萬港幣的研

究資助，另一方面，結合香港大學多學科及國際網路優勢，作為共同研究合作者，得到 1.7 千多萬港幣的研究

資助，並與英國，美國，加拿大，日本和中國內地形成了廣泛的學術合作。在多年中西醫結合和應用現代科學

技術研究中醫藥的基礎上，建立了肝腎疾病、糖尿病、腫瘤及炎症等技術平臺，主要應用藥理學，免疫學，細

胞分子生物學和組學技術和方法開展對中藥單、複方及有效成分在癌症和肝腎及糖尿病等方面的基礎和臨床研

究。馮奕斌博士的研究團隊會堅持與不同學科的醫生和科學家合作，發揮中藥多成分，多靶點的特點和優勢，

從科學的觀點和中西醫合作的角度，開展對不同腫瘤的基礎和臨床研究，重視癌症相關疾病的研究，如代謝性

疾病，從癌症患者的實際出發，辨證論治，與西醫藥優勢互補，並從中醫藥這個偉大寶藏中，為癌症患者提供

中醫藥抗癌的新療法，新藥物，補充替代療法和新的支持療法。

他的研究團隊學術上的成就，體現在保肝，保腎，降糖，抗炎，抗氧化，細胞死亡，抗腫瘤中藥的物質基

礎和分子作用機制研究，瀕危中藥的替代研究，中醫藥方法學和中醫藥教育研究，主要集中在肝腎疾病病、癌

症和糖尿病的中西醫結合研究上。至 2018 年 1 月, 總的出版物 368，在國內外權威學術期刊上發表了學術論文

130篇（中文 29，英文 96，日文 5），著作 25部（主編中文著作 3，參編英文著作 13，中文著作 7，翻譯著作

2），獲得或授權中國專利 3項，PCT專利 1項，國內外會議論文或擇要 201篇（中文 39，日文 19，英文 143），

其他 15，作為大會基調演講，大會演講及國內外特邀講座 80餘次. 馮奕斌博士作為第一作者和通訊作者，衝擊

因數超過 5 分的 SCI 論文 10 篇，其他 SCI 論文也多排在相關研究領域的前 5 位和品質 1 類的雜誌 (Journal of

Enthnopharmacology (IF 3.05), British journal of Pharmacology (IF5.2), PLOS ONE (IF4.6), Molecular cancer (IF 5.30),

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (IF5.089), BBA-Molecular Cell Research (IF 5.297),

BBA- Gene Regulatory Mechanisms (IF5.440), Oncotarget (6.395), Cell death and Disease (IF5.5), BBA - Molecular

and Cell Biology of Lipids, (IF 5.55), Science Supplement (IF31), autophagy (IF11.5) and Theranostics (IF 8.85) etc.)，

在學術界被高度關注和引用，如"Berberine and Coptidis Rhizoma as novel antineoplastic agents: A review of

traditional use and biomedical investigations"2009 年發表在 Journal of Ethnopharmacology, 於 2014 年 9 月流覽該雜

誌時（5 年為一個統計節點），是 2009 年以來引用率最高的 25 篇論文中被列為第一位，迄今引用率 373 次

（2018年 1月）在世界上開創了黃連和黃連素抗惡性腫瘤的熱門話題，他的保肝抗惡性腫瘤的原創性研究也一

直站在國際傳統醫藥和民族醫藥學界研究領域的前沿，而以黃連作為熊膽替代品的研究，在學術和社會上也產

生了很大影響，如 2008 年 10 月被香港及國內外媒體廣泛報導，2010 年 8 月在英國參加國際大會時被邀請到

BBC 中央演播室接受採訪, 2013 年 6 月香港大學公報報導了他研究熊膽替代品及新藥開發的故事，熊膽替代品

的其中一篇論文發表在 Journal of Ethnobiology and Ethnomedicine，被列為高度關注的論文，迄今被下載流覽了

3.6萬多次（至2018年1月），並為國際雜誌（Chinese Medicine，Evidence-Based Complementary and Alternative

medicine）於 2011 年和 2016 年分別主編過兩個肝病相關的特別系列。

14

教學經歷

先後從事過中藥學, 免疫中藥學，中藥藥理學，中藥毒理學, 中醫養生學，中醫腫瘤學，中醫內科學和西藥藥理

學的教學。目前主要擔任臨床中藥學,中藥藥理學和中藥毒理學的教學。

臨床專長

主要從事中醫藥治療內科雜症臨床工作, 長於腫瘤、慢性肝腎疾病、部分內分泌代謝性疾病和自身免疫性疾病

等的診治, 腫瘤如肺癌、鼻咽癌、腸癌、肝癌、胰腺癌、胃癌、食道癌、腦膠質瘤等；其他疾病如代謝綜合症、

牛皮癬、糖尿病、慢性肝炎、慢性腎炎、腎病綜合征等。

主要代表性論著（*通訊作者）

1. Wang N, Tan HY, Li S, Feng Y*. Atg9b Deficiency Suppresses Autophagy and Potentiates Endoplasmic Reticulum

Stress-Associated Hepatocyte Apoptosis in Hepatocarcinogenesis. Theranostics. 2017, accepted for publication (IF

= 8.854, 5-year IF).

2. Cheng Y, Feng Y, Xia Z, Li X, Rong J*. <omega>-Alkynyl arachidonic acid promotes anti-inflammatory

macrophage M2 polarization against acute myocardial infarction via regulating the cross-talk between PKM2, HIF-

1<alpha> and iNOS. BBA - Molecular and Cell Biology of Lipids. Accepted for publication, 2017. (IF 5.55)

3. Hung J, Cao S, Tang H, He Y, Feng Y, Wang K, Zhang QS. Molecular targets and associated potential pathways of

Danlu capsules in hyperplasia of mammary glands based on systems pharmacology. Evidence-Based

Complementary and Alternative Medicine 2017, (IF1.931, 5-year IF2.014. Ever ranking No.1 with IF 4.774 in

Category of Integrative & Complementary Medicine in 2012).

4. Hong M, Li S, Tan HY, Cheung F, Wang N, Huang J, Feng Y*. A network-based pharmacology study of the

potential hepatotoxicity of traditional hepatoprotective Chinese herbal medicines. Molecules 2017, 22, 632;

doi:10.3390/molecules22040632 (IF 2.465, 5-year IF 2.749).

5. Hong M, Li S, Wang N, Tan HY, Cheung F, Feng Y*. A Biomedical Investigation on the Hepatoprotective Effect

of Radix Salviae Miltiorrhizae and Network pharmacology-based Prediction of the Active compounds and

Molecular Targets. International Journal of Molecular Sciences 2017, accepted for publication. (IF 3.257, 5-Year

IF 3.213).

6. Lan J, Wang N, Huang L, Liu Y, Ma X, Lou H, Chen C, Feng Y*, Pan W. Design and synthesis of novel tetrandrine

derivatives as potential anti-tumor agents against human hepatocellular carcinoma. European Journal of Medicinal

Chemistry. 2017 Feb 15;127:554-566. doi:10.1016/j.ejmech.2017.01.008. (IF 3.902, 5-year IF 3.982).

7. Tan HY, Wang NM, Tsao SW, Che CM, Yuen MF, Feng Y*. IRE1α Inhibition by Natural Compound Genipin on

Tumour Associated Macrophages Reduces Growth of Hepatocellular Carcinoma. Oncotarget. 2016 May 30. doi:

10.18632/oncotarget.9696. [Epub ahead of print] (IF 6.359, 5-year IF 6.368)

8. Feng Y*, Yuen MF, Xu Q, Wan XY, Wang DQ. Herbal medicine new exploration in hepatology. Evidence-Based

Complementary and Alternative Medicine. 2016; Editorial. 2016:3056438. doi: 10.1155/2016/3056438. Epub 2016

Jul 20. (IF 1.931, 5-year IF 2.014. Ever ranking No.1 with IF 4.774 in Category of Integrative & Complementary

Medicine in 2012)

9. Tan HY, Wang N, Man K, Tsao SW, Che CM, Feng Y*. Autophagy-induced RelB/p52 activation mediates tumor

associated macrophage repolarisation and suppression of hepatocellular carcinoma by natural compound baicalin.

Cell Death and Disease 2015; 6, e; doi:10.1038/cddis.2015.271 (Nature group, IF 5.378, 5years IF 6.03).

10. Li H, Wang X, Liu Y, Pan D, Wang Y, Yang N, Xiang L, Cai X, Feng Y*. Hepatoprotection and hepatotoxicity of

Heshouwu, a Chinese medicinal herb: context of the paradoxical effect. Food and Chemical Toxicology, 2016 Jul

30. pii: S0278-6915(16)30264-2. doi: 10.1016/j.fct.2016.07.035. [Epub ahead of print] (IF 3.584 and the 5-Year IF

3.440).

11. Tan HY, Wang N, Takahashi M, Feng YG, Li HY, Feng Y*. New Natural Pigment Fraction Isolated from Saw

Palmetto: Potential for adjuvant therapy of Hepatocellular Carcinoma. International Journal of Molecular Sciences,

2016 Aug 5; 17(8). pii: E1277. doi: 10.3390/ijms17081277. (IF 3.257, and the 5-Year Impact Factor is 3.213).

12. Chan KW, Ip TP, Kwong AS, Lui SL, Chan GC, Cowling BJ, Yiu WH, Wong DW, Liu Y, Feng Y, Tan KC, Chan

LY, Leung JC, Lai KN, Tang SC. Semi-individualized Chinese Medicine Treatment as an Adjuvant Management

15

for Diabetic Nephropathy – A pilot add-on, randomised, controlled, multi-centre, open-label pragmatic clinical trial.

BMJ Open，2016 Aug 5;6(8):e010741. doi: 10.1136/bmjopen-2015-010741 (IF 2.562).

13. Hong M, Tan HY, Li S, Cheung F, Wang N, Nagamatsu T, Feng Y*. Cancer stem cells: the potential targets of

Chinese medicines and their active compounds. International Journal of Molecular Sciences, 2016 Jun 7;17(6). pii:

E893. doi: 10.3390/ijms17060893. Review. (IF3.257, and the 5-Year Impact Factor is 3.213).

14. Wang N, Xu Q, Tan HY, Hong M, Li S, Yuen MF, Feng Y*. Berberine inhibits fibrogenesis in a rat model of liver

fibrosis and in hepatic stellate cells. Evidence-Based Complementary and Alternative Medicine. 2016:8762345. doi:

10.1155/2016/8762345. Epub 2016 Apr 30. (IF1.931, 5-year IF2.014. Ever ranking No.1 with IF 4.774 in Category

of Integrative & Complementary Medicine in 2012)

15. Tan HY, Wang N, Li S, Hong M, Wang X, Feng Y*. The reactive oxygen species in macrophage polarization:

reflecting its dual role in progression and treatment of human diseases. Oxidative Medicine and Cellular Longevity.

2016; 2016:2795090. doi: 10.1155/2016/2795090. Epub 2016 Apr 6. Review. (IF 4.492, 5-year IF 4.667)

16. Wang X, Wang N, Li H, Liu M, Cao F, Yu X, Zhang J, Tan Y, Xiang L, Feng Y*. Up-Regulation of PAI-1 and

Down-Regulation of uPA Are Involved in Suppression of Invasiveness and Motility of Hepatocellular Carcinoma

Cells by a Natural Compound Berberine. International Journal of Molecular Science. 2016 Apr 16;17(4). pii: E577.

doi: 10.3390/ijms17040577. (IF3.257, and the 5-Year IF 3.213)

17. Li S, Tan HY, Wang N, Hong M, Li L, Cheung F, Feng Y*. Substitutes for bear bile for the treatment of liver

diseases: research progress and future perspective. Evidence-Based Complementary and Alternative Medicine.

2016:4305074. doi: 10.1155/2016/4305074. Epub 2016 Mar 21. Review. (IF1.931, 5-year IF2.014. Ever ranking

No.1 with IF 4.774 in Category of Integrative & Complementary Medicine in 2012)

18. Lam P, Cheung F, Tan HY, Wang N, Yuen MF, Feng Y*. Hepatoprotective effect of Chinese medicinal herbs: a

review with focus on its anti-inflammatory and anti-oxidative activities. International Journal of Molecular Science.

2016 Mar 29;17(4). pii: E465. doi: 10.3390/ijms17040465. Review. (IF3.257, 5-Year IF 3.213)

19. Tan HY, San-Marina S, Wang N, Hong M, Li S, Li L, Cheung F, Wen XY, Feng Y*. Preclinical models for

investigation of herbal medicines in liver diseases: update and perspective. Evidence-Based Complementary and

Alternative Medicine. 2016; 2016:4750163. doi: 10.1155/2016/4750163. Epub 2016 Jan 28. Review. (IF1.931, 5-

year IF2.014. Ever ranking No.1 with IF 4.774 in Category of Integrative & Complementary Medicine in 2012)

20. Li H, Cao S, Wang X*, Zuo Q, Chen P, Liu Y, Liu M, Feng Y*. Quality Evaluation of Heshouwu, a Taoist Medicine

in Wudang, China. Experimental and Therapeutic Medicine, 2016 Oct;12(4):2317-2323.

21. Liu JY, Chen XX, Tang SC, Sze SC, Feng Y, Lee KF, Zhang KY*. Chinese medicines in the treatment of

experimental diabetic nephropathy. Chinese Medicine. 2016 Feb 24;11:6. doi: 10.1186/s13020-016-0075-z.

(IF2.234)

22. Klionsky DJ*,…Feng Y, …et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd

edition). Autophagy. 2016 Jan 2; 12(1):1-222. (IF 11.753, and the 5-Year Impact Factor is 11.958).

23. Wang N, Tan HY, Li L, Yuen MF, Feng Y*. Berberine and Coptidis Rhizoma as potential anticancer agents: Recent

updates and future perspectives. J Ethnopharmacol. 2015 Dec 24;176:35-48. doi: 10.1016/j.jep.2015.10.028. Epub

2015 Oct 19. Review.

24. Wang L, Wang N, Tan H, Zhang Y, Feng Y*. Protective Effect of a Chinese Medicine Formula He-Ying-Qing-Re

Formula on Diabetic Retinopathy. Journal of Ethnopharmacology. 2015 Jul 1;169:295-304. (IF 3.04, 5 year IF 3.728,

1/22, Q1, No.1 in Category of Integrative & Complementary Medicine)

25. Wang N, Zhu M, Wang X, Tan HY, Tsao SW, Feng Y*. Berberine-induced tumor suppressor p53 up-regulation gets

involved in the regulatory network of MIR-23a in hepatocellular carcinoma. Biochim Biophys Acta (BBA) - Gene

Regulatory Mechanisms. 2014 Sep;1839(9):849-57. [IF 6.332].

26. Tsang CM, Cheung KC, Cheung YC, Man K, Lui VW, Tsao SW, Feng Y*. Berberine suppresses Id-1 expression

and inhibits the growth and development of lung metastases in hepatocellular carcinoma. Biochimica et Biophysica

Acta (BBA) -Molecular Basis of Disease 2015 Mar;1852(3):541-51. (IF 5.089, 5 year IF 5.13, Q1 in Molecular

medicine).

27. Xu Q, Feng Y, Duez P, Hendry BM, Hylands PJ. The hunt for anti-fibrotic and pro-fibrotic botanicals. The Art and

Science of Traditional Medicine Part 1: TCM Today – A Case for Integration, Science 2014;346 (6216 Suppl), S19-

S20. (IF 31.477, 5 year IF 34.463, 2/55, Q1, No.2 in Category of Multidisciplinary Sciences)

28. Wang N, Feng Y*, Zhu M, Siu FM, Ng KM, Che CM*. A Novel Mechanism of XIAP Degradation Induced by Timosaponin AIII in Hepatocellular Carcinoma. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research

2013 Jul 29;1833(12):2890-2899. doi: 10.1016/j.bbamcr.2013.07.018. (IF 5.38, 5 years IF 4.814)




16



analysis of randomized controlled trials. Evidence-Based Complementary and Alternative Medicine 2013:487919.

doi: 10.1155/2013/487919. Epub 2013 Jul 17. (IF4.774)

30. Wang N, Zhu M, Tsao SW, Man K, Zhang ZJ, Feng Y*. MiR-23a-Mediated Inhibition of Topoisomerase 1

Expression Potentiates Cell Response to Etoposide in Human Hepatocellular Carcinoma. Molecular Cancer 2013

Oct 8; 12(1):119. (IF 5.40)

31. Wang N, Pan W, Zhu M, Zhanf M, Hao X, Liang G, Feng Y*. Fangchinoline induces autophagic cell death via

p53/sestrin2/AMPK signaling in human hepatocellular carcinoma cells. British Journal of Pharmacology.

2011;164(2b):731-742. (IF 5.209, total no. of citations since publication is 22 by Google scholar).


activities and Suppresses the Metastatic Potential of Human Hepatocellular Carcinoma. PLOS ONE,

2012;7(9):e46318. doi: 10.1371/ journal.pone.0046318. (IF 4.092, 5 year IF 4.532).

33. Wang N, Feng Y*, Tan HY, Cheung F, Hong M, Lao L, Nagamatsu T. Inhibition of Eukaryotic Elongation Factor-

2 Confers to Tumor Suppression by a Herbal Formulation Huanglian-Jiedu Decoction in Human Hepatocellular

Carcinoma. Journal of Ethnopharmacology, 2015 Feb 17. pii: S0378-8741(15)00103-8. doi:

10.1016/j.jep.2015.02.025. (IF 3.04, 5 year IF 3.728, 1/22, Q1, No.1 in Category of Integrative & Complementary

Medicine)

34. Li H, Cao S, Wang X*, Zuo Q, Chen P, Liu Y, Liu M, Feng Y*. Quality Evaluation of Heshouwu, a Wudang Taoist

Medicine in China. Exp. Ther. Med., 2015 Accepted for publication.

35. Klionsky DJ*,…Feng Y, …et al. Guidelines for the Use and Interpretation of Assays for Monitoring Autophagy

(2nd edition). Autophagy 2015, accepted for publication (IF11.753).

36. Wang X*, Xiang L, Li H, Chen P, Feng Y, Zhang J, Yang N, Li F, Wang Y, Zhang Q, Li F, Cao F. The Role of

HMGB1 Signaling Pathway in the Carcinogenesis and Progress of Hepatocellular Carcinoma: a Review.

International Journal of Molecular Science 2015 Sep 17;16(9):22527-40. doi: 10.3390/ijms160922527. (IF2.862)


Achievements and Artifacts in State-of-Art. Biomed Res Int. 2015;2015:934207. doi: 10.1155/2015/934207. Epub

2015 Mar 3. [IF 2.706, 5 year IF 2.750].



Cancer therapy 2015 Jan;14(1):75-85. doi: 10.1177/1534735414550036. Epub 2014 Sep 15. (IF 2.354, 5 year IF

2.479).


hepatocellular carcinoma: Current progress on pharmacological actions and mechanisms. Journal Integrative

Medicine. 2015; 13(3):142-64.

40. Wang X, Feng Y*, Wang N, Cheung F, Tan HY, Zhong S, Li C, Kobayashi S. Chinese Medicines Induce Cell Death:

The Molecular and Cellular Mechanisms for Cancer Therapy. Biomed Res Int. 2014;2014:530342. doi:

10.1155/2014/530342. Epub 2014 Oct 14. Review. [ IF 2.706, 5 year IF 2.750]

41. Xu B, Wang N, Pan W, Qiu J, Cao P, Zhu M, Feng Y*, Liang G*. Synthesis and anti-tumor activity evaluation of

Matijin-Su derivatives. Bioorg Chem. 2014 Jun 2;56C:34-40. doi: 10.1016/j.bioorg.2014.05.009. [Epub ahead of

print] [IF 2.141, 5 year IF 1.720]


osteoporosis in vivo. Exp. Ther. Med., 2014 Jun;7(6):1687-1690. Epub 2014 Apr 2. [IF1.268, 5 year IF]


conventional medical institute. J. Integr. Med., 2014 May;12(3):187-90. doi: 10.1016/S2095-4964(14)60027-3.


http://dx.doi.org/10.4172/2167-7700.1000130.

45. Tan HY, Wang N, Tsao SW, Zhang ZJ, Feng Y*.Suppression of Vascular Endothelial Growth Factor via Inactivation

of Eukaryotic Elongation Factor-2 by Alkaloids in Coptidis rhizoma in Hepatocellular Carcinoma. Integrated

Cancer therapy 2014 Sep;13(5):425-34. (IF 2.354, 5 year IF 2.479).

46. Wang N, Feng Y*. Elaborating the Role of Natural Products-Induced Autophagy in Cancer Treatment: Achievements and Artifacts in State-of-Art. Biomed Res Int. Accepted for publication. [IF 2.706, 5-year IF 2.750].


17


Cancer therapy 2015 Jan;14(1):75-85. doi: 10.1177/1534735414550036. Epub 2014 Sep 15. (IF 2.354, 5-year IF

2.479).


hepatocellular carcinoma: Current progress on pharmacological actions and mechanisms. J Integr Med. 2015; 13(?):

000-000. accepted January 27, 2015.

49. Wang X, Feng Y*, Wang N, Cheung F, Tan HY, Zhong S, Li C, Kobayashi S. Chinese Medicines Induce Cell Death:

The Molecular and Cellular Mechanisms for Cancer Therapy. Biomed Res Int. 2014;2014:530342. doi:

10.1155/2014/530342. Epub 2014 Oct 14. Review. [ IF 2.706, 5-year IF 2.750]

50. Wang N, Zhu M, Wang X, Tan HY, Tsao SW, Feng Y*. Berberine-induced tumor suppressor p53 up-regulation gets

involved in the regulatory network of MIR-23a in hepatocellular carcinoma. Biochim Biophys Acta. 2014 Jun 3.

pii: S1874-9399(14)00141-2. doi: 10.1016/j.bbagrm.2014.05.027.

51. Xu B, Wang N, Pan W, Qiu J, Cao P, Zhu M, Feng Y*, Liang G*. Synthesis and anti-tumor activity evaluation of

Matijin-Su derivatives. Bioorg Chem. 2014 Jun 2;56C:34-40. doi: 10.1016/j.bioorg.2014.05.009. [Epub ahead of

print]


osteoporosis in vivo. Exp Ther Med. 2014 Jun;7(6):1687-1690. Epub 2014 Apr 2.


conventional medical institute. J Integr Med. 2014 May;12(3):187-90. doi: 10.1016/S2095-4964(14)60027-3.


http://dx.doi.org/10.4172/2167-7700.1000130.

55. Tsang CM, Cheung YC, Lui VW, Yip YL, Zhang G, Lin VW, Cheung K, Feng Y*, Tsao SW*. Berberine suppresses

tumorigenicity and growth of nasopharyngeal carcinoma cells by inhibiting STAT3 activation induced by tumor

associated fibroblasts. BMC Cancer. 2013 Dec 31; 13(1):619. doi: 10.1186/1471-2407-13-619.

56. Feng Y*, Wang N. The new generation of drug discovery and its analytical technologies. Editorial. Bioequivalence

& Bioavailability 2013,5:e42.doi:10.4172/ jbb.10000e42.

57. Tan HY, Wang N, Tsao SW, Zhang Z, Feng Y*. Suppression of Vascular Endothelial Growth Factor via Inactivation

of Eukaryotic Elongation Factor-2 by Alkaloids in Coptidis rhizoma in Hepatocellular Carcinoma. Integrated

Cancer therapy 2013 Dec 19. [Epub ahead of print].

58. Wang D, Wong HK, Feng Y, Zhang ZJ. Liquiritigenin exhibits antitumour action in pituitary adenoma cells via

Ras/ERKs and ROS-dependent mitochondrial signalling pathways. J Pharm Pharmacol. 2014 Mar;66(3):408-17.

doi: 10.1111/jphp.12170. Epub 2013 Nov 6.

59. Wang D, Wong HK, Feng Y, Zhang ZJ.18beta-Glycyrrhetinic acid induces apoptosis in pituitary adenoma cells via

ROS/MAPKs-mediated pathway. J Neurooncol. 2014 Jan;116(2):221-30. doi: 10.1007/s11060-013-1292-2. Epub

2013 Oct 27.

60. Wang N, Zhu M, Tsao SW, Man K, Zhang Z, Feng Y*. MiR-23a-mediated inhibition of topoisomerase 1 expression

potentiates cell response to etoposide in human hepatocellular carcinoma. Mol Cancer. 2013 Oct 8;12(1):119. doi:

10.1186/1476-4598-12-119.

61. Zhang Q, Li H, Wang S, Liu M, Feng Y, Wang X. Icariin protects rat cardiac H9c2 cells from apoptosis by inhibiting

endoplasmic reticulum stress. Int J Mol Sci. 2013 Aug 30;14(9):17845-60. doi: 10.3390/ijms140917845.


Timosaponin AIII in Hepatocellular Carcinoma. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research

2013; 1833(12):2890-2899. doi: 10.1016/j.bbamcr.2013.07.018.



analysis of randomized controlled trials. Evidence-Based Complementary and Alternative Medicine 2013:487919.

doi: 10.1155/2013/487919.

64. Wang D, Wong HK, Feng Y, Zhang ZJ. Paeoniflorin, a natural neuroprotective agent, modulates multiple anti-

apoptotic and pro-apoptotic pathways in differentiated PC12 cells. Cell Mol Neurobiol. 2013 May;33(4):521-9. doi:

10.1007/s10571-013-9914-y. Epub 2013 Feb 24.

65. Wang N, Feng Y*, Zhu M, Chow O, Wang XB, Su W, Tong Yao. A Comparative Study on the Hepatoprotective Action of Coptidis Rhizoma Aqueous Extract and Bear Bile on Carbon Tetrachloride induced Liver Fibrosis in Rats.

BMC Complement Altern Med. 2012;12(1):239.












18


activities and Suppresses the Metastatic Potential of Human Hepatocellular Carcinoma. PLoS One.

2012;7(9):e46318.

67. To CS, Liew C, Wang XB, Wang N, Feng Y*. Comparison of Components and Anti-Liver Cancer Activity in vitro

between Huanglian and Yunlian. Journal of Bioequivalence & Bioavailability 2012, 4: 086-090. doi:

10.4172/jbb.10000118.

68. Wang XB, Feng Y*, Wang N, Cheung F, Wong CW. Recent Progress on Anti-Liver Fibrosis Candidates in Patents

of Herbal Medicinal Products. Recent Pat Food Nutr Agric. 2012; 4:91-106.

69. Wang D, Wong HK, Zhang L, McAlonan GM, Wang XM, Sze SC, Feng YB, Zhang ZJ. Not only dopamine D(2)

receptors involved in Peony-Glycyrrhiza Decoction, an herbal preparation against antipsychotic-associated

hyperprolactinemia. Prog Neuropsychopharmacol Biol Psychiatry 2012; 39(2):332-8.

70. Wang XB, Feng Y*, Wang N, Cheung F, Wong CW. Recent Progress on Anti-Liver Fibrosis Candidates in Patents

of Herbal Medicinal Products. Recent Pat Food Nutr Agric. 2012 Aug 1;4(2):91-106.

71. Hirasawa Y, Nishiyama T, Nagao T, Feng Y, Nagamatsu T. Involvement of Protein Kinase C in Reduction of

Aggregated Protein and Phosphorylation of CREB in Glomeruli. Experimental Animals 2012;61(2):119-24

72. Cheung F, Feng Y*, Wang N, Yuen MF, Tong Y, Wong VT. Effectiveness of Chinese herbal medicine in treating

liver fibrosis: a systematic review and meta-analysis of randomized controlled trials. Chin Med. 2012 Feb 29; 7(1):5.

73. Hirasawa Y, Sakai T, Ito M, Yoshimura H, Feng Y, Nagamatsu T. Advanced-glycation-end-product-cholesterol-

aggregated-protein accelerates the proliferation of mesangial cells mediated by transforming-growth-factor-beta 1

receptors and the ERK-MAPK pathway. European Journal of Pharmacology 2011 Dec 15;672(1-3):159-68.

74. Feng Y*, Wang N, Ye X, Li H, Feng Y, Cheung F, Nagamatsu T. Hepatoprotective effect and its possible mechanism

of Coptidis rhizoma aqueous extract on carbon tetrachloride-induced chronic liver hepatotoxicity in rats. Journal of

Ethnopharmacology 2011 Dec 8;138(3):683-90. doi: 10.1016/j.jep.2011.09.032.

75. Wang N, Pan W, Zhu M, Zhanf M, Hao X, Liang G*, Feng Y*. Fangchinoline induces autophagic cell death via

p53/sestrin2/AMPK signaling in human hepatocellular carcinoma cells. British Journal of Pharmacology

2011;164(2b):731-742.

76. Zhang ZJ, Tan QR, Tong Y, Wang XY, Wang HH, Ho LM, Wong HK, Feng Y, Wang D, Ng R, McAlonan GM,

Wang CY, Wong VT. An epidemiological study of concomitant use of chinese medicine and antipsychotics in

schizophrenic patients: implication for herb-drug interaction. PLoS One 2011;6(2):e17239.

77. Feng Y*, Wang N, Zhu M, Feng YG, Li HY, Tsao SW. Recent progress on anticancer candidates in herbal medicinal

products. Recent patent in Food, Nutrition & Agriculture. 2011, 3(1):30-48.

78. Wang N, Feng Y*, Xie TN, Su W, Zhu M, Chow O, Zhang Y, Ng KM, Leung CH, Tong Y. Chemical and biological

analysis of active free and conjugated bile acids in animal bile by using HPLC-ELSD and MTT methods.

Experimental and Therapeutic Medicine 2011, 2: 125-130.

79. Zhu M, Wang N, Tsao S, Yuen M, Feng YG, Wan Thomas SK, Man K, Feng Y*. Up-regulation of microRNAs,

miR21 and miR23a, in human liver cancer cells treated with Coptidis Rhizome aqueous extract. Experimental and

Therapeutic Medicine 2011, 2: 27-32.

80. Ng ZB, Xiao L, Feng Y, Tong Y, Wong JH, Yao RM, Li L, Mo FZ, Xiao Y, Shaw PC, Li ZM, Sze CW, Zhang Y. Dendrobium candidum extract increases the expression of aquaporin 5 in labial glands from patients with Sjögren’s

Syndrome. Phytomedicine 2011;18(2-3):194-8.

81. Wang N, Feng Y*, Lau EP, Tsang C, Ching Y, Man K, Tong Y, Nagamatsu T, Su W, Tsao S. F-actin reorganization

and inactivation of rho signaling pathway involved in the inhibitory effect of Coptidis Rhizoma on hepatoma cell

migration. Integrate Cancer Therapy 2010, 9(4):354-64.

82. Wang N, Feng Y*, Zhu M, Tsang CM, Man K, Tong Y, Tsao SW. Berberine induces autophagic cell death and

mitochondrial apoptosis in liver cancer cells: the cellular mechanism. Journal of cellular biochemistry 2010,

111(6):1426-36.

83. Feng Y*, Siu KY, Ye X, Wang N, Yuen MF, Leung CH, Tong Y, Kobayashi S. Hepatoprotective effects of berberine

on carbon tetrachloride- induced acute liver hepatotoxicity in rats. Chinese Medicine 2010, 5:33 (1-6).

84. Lin X, Sze CW, Tong Y, Zhang Z, Feng Y, Chen JP, Ng TB, Lin X, Shaw PC, Zhang Y. Protective Effect of

Dendrobium officinale Polysaccharides on Experimental Sjogren's Syndrome. Journal of Complementary and

Integrative Medicine 2010, 7(1): DOI: 10.2202/1553-3840.1342. 85. Feng Y, Cheung KF, Wang N, Liu P, Nagamatsu T, Tong Y*. Chinese medicines as a resource for liver fibrosis

treatment. Chinese Medicine 2009; 4(1):16(1-11).











19

86. Tang J, Feng Y*, Tsao S, Wang N, Curtain R, Wang Y. Berberine and Coptidis Rhizoma as novel antineoplastic

agents: A review of traditional use and biomedical investigations. Journal of Ethnopharmacology 2009; 126:5-17.

87. Tsang CM+, Lau Echo PW+, Di K, Cheung PY, Hau PM, Ching YP, Wong YW, Cheung Annie LM, Wan Thomas

SK, Tong Y, Tsao SW* and Feng Y*. Berberine inhibits RhoGTPases and cell migration at low doses but induces

G2 arrest and apoptosis at high doses in human cancer cells. International Journal of Molecular Medicine 2009;

24:131-138.

88. Ye XS, Feng Y*, Tong Y, Ng KM, Tsao SW, Lau George KK, Sze CW, Zhang YB, Tang J, Shen JG, Kobayashi S.

Hepatoprotective effects of Coptidis Rhizoma aqueous extract on carbon tetrachloride-induced acute liver

hepatotoxicity in rats. Journal of Ethnopharmacology 2009; 124:130–136.

89. Feng Y*, Siu K, Wang N, Ng KM, Tsao SW, Nagamatsu T, Tong Y. Bear bile: dilemma of traditional medicinal use

and animal protection. Journal of Ethnobiology and Ethnomedicine 2009, 5:2 (1-9).

90. Wang N, Wang Y, Li P, Peng W, Xie T, Feng Y, Su W. The Bioavaliability of Hepatoprotective Flavoniods in

Hypericum Japonicum Extract. Journal of Bioanalysis & Biomedicine. 2009 1(1):33-8.

91. Hirasawa Y, Matsui Y, Ohtsu S, Yamane K, Toyoshi T, Kyuki K, Sakai T, Feng Y, Nagamatsu T*. Involvement of

hyperglycemia in deposition of aggregated protein in glomeruli of diabetic mice. European Journal of

Pharmacology 2008, 601(1-3):129-35.

92. Tang J, Feng Y*, Tong Y, Yap M, Man YK*. A distinct new microscopic feature for identification of the crude drug

of Radix Angelicae Pubescentis. Journal of Chinese Medicinal Materials 2008, 31(12):1796-1802.

93. Tang J, Feng Y, Tong Y, Jia RR, SY LK, Man RK. Identification of mucilage cavity as a significant microscopic

characteristic existing in phloem instead of pith of Radix et Rhizoma Rhei. Wuhan University Journal of Natural

Sciences 2008, 13(2): 239-246.

94. Sze SC, Song JX, Wong RN, Feng Y, Ng TB, Tong Y*, Zhang KY*. Application of SCAR (sequence characterized

amplified region) analysis to authenticate Lycium barbarum (wolfberry) and its adulterants. Biotechnol Appl

Biochem 2008, 51(Pt 1):15-21.

95. 杜永達, 馮奕斌*. 代謝綜合症中醫治療及病案分析一例. 香港中醫雜誌. 2015, 10(2):54-58.

96. 王蕾蕾，王甯，馮奕斌*，張殷建*.中藥治療糖尿病視網膜病變臨床與基礎研究進展.中國中醫眼科雜誌，

2014，24(3): 227-232.

97. 林蓓茵，馮奕斌*. 糖尿病合併結直腸癌關係探討及中藥免煎顆粒治療驗案一例. 香港中醫雜誌. 2014,

9(1):31-36.

98. 陳雷，張凡，馮奕斌*. 中醫藥防治原發性肝癌的臨床研究進展. 香港中醫雜誌 2013, 8(2):80-86.

99. 林蓓茵，馮奕斌*. 糖尿病合併膽管癌關係探討及病案分析一例. 香港中醫雜誌 2013, 8(1):26-29.

100. 林小珊，馮奕斌*. 香砂六君湯合葛根芩連湯治療大腸癌經驗探析.香港中醫雜誌 2011, 6(3):35-38.

101. 林小珊，馮奕斌*. 清熱類中藥抗腫瘤的作用特點及作用機制研究進展.香港中醫雜誌 2009, 4(1):97-105.

102. 馮奕斌*，羅偉權，朱世清. 從黃連及其複方古今臨床應用，發掘現代臨床新應用. 中國中藥雜誌 2008,

33(10):1221-1225. 北京.

103. 馮奕斌*, 童瑤. 從中藥現代研究看中醫學的基本特點. 香港中醫雜誌, 2008; 3 (1): 17-21. 香港.

104. 馮奕斌*，葉星沈，童瑤. 建立香港中藥不良反應監測系統和發揮中醫藥在香港藥物濫用防治中的作用. 中

國藥物濫用防治雜誌 2007; 13(4):220-223. 北京.

105. 馮奕斌*，陳抗生. 國內外資料庫中對中藥不良反應和中毒的基本情況及述評.香港中醫雜誌 2007; 2(1):27-

33. 香港.

106. 馮奕斌*, 童瑤, 劉蘋迴.中藥複方研究之探討.香港中醫雜誌，2006;1(2): 64-67. 香港.

107. 馮奕斌, 童瑤, 湯俊，朱世清.試論香港的中藥標準化, 上海中醫藥雜誌 2005; 39(10):3-4. 上海.

108. 馮奕斌*. 中藥學的教學構思和實踐. 中國中醫藥現代遠程教育 2004; 2 (8):38-40. 北京.

109. 馮奕斌*.中藥現代化研究及其展望. 亞太生技 2004;2(1):48-52. 新加坡.

110. 羅偉權, 馮奕斌. 腸瘤消對大腸腺瘤及其癌變患者術後鞏固治療的臨床觀察. 中醫雜誌 2004;45:78-79. 北京.

111. Luo WQ, Hui SC, Chan TY and Feng Y. Inhibitory Effect of Water Extract from Golden Thread on Leukemia T,

Feng YG, Kobayashi S and Koike T. Pharmacological studies of diuretic TCM formulations: ita L-1210 Cells

Cultured in vitro. Pharmacologist, 2002; 44(2):193. USA.

20

112. Feng Y, Nagamatu T, Suzuki Y, Kawats application and evaluation of Pharmacological screening. Journal of

Traditional Medicines, 2000; 17(3), 122-130. Toyama, Japan.

113. Tarao F, Morimoto M, Feng Y and Kobayashi S(1999). Effect of heat inactivation of serum samples on soluble Fas

measurement. Annual reports in Hokkaido University, pp.1-8. Sapporo, Japan.

114. Kobayashi S, Feng Y. Fas and Fas ligand in autoimmue diseases. Journal of Modern Medicine and Medical

Technology,1998;30(1):282-285. Tokyo, Japan.

115. Feng Y. Studies on Fas Ligand Expression in Patients with Systemic Lupus Erythematosus. Hokkaido Journal of

Medical Science, 1997; 72(4), 443-455. Sapporo, Japan.

116. Jodo S, kobayashi S, kayagaki N, Ogura N, Feng Y, Amasaki Y, Fujisaku A, Azuma M, Yagita H, Okumura K and

Koike T. Serum levels of soluble Fas APO-1(CD95) and its molecular structure in patients with systemic lupus

erythematosus (SLE) and other autoimmune diseases. Clin Exp Immunol, 1997;107:89-95. New York, USA.

117. Feng Y, Nagamura T, Suzuki Y, Kawada T, Koike T. The diuretic effects of Chinese medicine prescription on

normal rats and various pathological models. Journal of Traditional Medicines, 1996; 13(4):484-485. Toyama,

Japan.

118. 馮奕斌. 解表祛邪治狐惑. 成都中醫學院學報 1991;14(1):19-20.成都.

119. 馮奕斌. 中藥的現代臨床研究. 雲南中醫學院學報，1987;10(4): 7-10.昆明.

書籍出版 (*主編或通訊作者)

1. 陳長勳主編，編委操紅纓，陳蘭英，陳艷芬，方曉艷，馮奕斌，顧偉梁，顧勇，華永慶，黃莉莉，聶紅，

屈飛，沈雲輝，秦濟成，王斌，王佳，汪寧，汪選斌，王艷艷，徐海波，於爽，張璟璿. 中藥藥理學 (英文

版，全國中醫藥行業高等教育“十三五”創新教材). 中國中醫藥出版社, 第一版，2017. 中國北京. Pp267.

2. 陳德興主編, 文小平, 嚴世芸主審. 編委陳寶忠, 陳德興, 都廣禮, 範穎, 馮奕斌, 胡方林, 華浩明, 賈波, 倪誠, 年

莉, 阮時寶, 王付, 王均甯, 文小平, 辛增平, 徐曉東, 於洋, 雲雪林. 方劑學（普通高等教育“十二五”規劃教材，

全國高等醫藥院校規劃教材）. 清華大學出版社，第一版，2013 年 12 月，中國北京. pp394.

3. Alan Worsley, Feng Y, Wang N, Ho Faith, Yu Edwin, Rose Mak. Use of Herbs in Chinese and Western Medicine

(天然知源). 香港醫學博物館, 雙語中文版英文版第一版, 2013. 中國香港. pp67.

4. 謝夢洲主編，譚興貴主審，編委：謝夢洲, 尚雲青, 易蔚, 周儉, 吳正治, 聶紅, 史麗萍, 田勝利, 馮奕斌, 孫兆

妹, 李海濤, 張賓, 林雅, 金紅, 周宜, 趙曉薇, 郭彤, 梁曉葳, 謝雪姣, 戴霞, 孫貴香. 中醫藥膳學（全國中醫藥行

業高等教育“十二五”規劃教材，全國高等中醫藥院校規劃教材）. 中國中醫藥出版社, 第二版，2013. 中國

北京. pp387.

5. Feng YG, Wang N, Chueng F, Zhu M, Li H, Feng Y*. Molecular and Cellular Mechanism Studies on Anticancer

Effects of Chinese Medicines. Chapter in Biomedical Engineering, Trends, Research and Technologies (pp331-

362). ISBN 978-953-307-514-3. 2011, pp644. (English).

6. Feng Y, Chen XM, Wang N and Shen JG. Current Progress on Medicinal Plants and their Biological Properties in

Contemporary China (Around 20,000 words). Chapter in Recent Progress in Medicinal Plants Vol. 28:

Ethnomedicine: Source & Mechanism-II. Studium Press LLC, USA. 2010, pp491-546. (English).

7. Tong Y and Feng Y. Assessments in the Bachelor of Chinese Medicine (BChinMed) Programme. Chapter in The

assessment of the University of Hong Kong. 2009, pp51-58. Published by Institute of Medical and Health Sciences

Education, Li Ka Shing Faculty of Medicine, The University of Hong Kong. (English).

8. 馮奕斌主編，編委劉克儉，王階，沈劍剛，張豔波，容建輝，童瑤，陳抗生，黃伯偉. 基礎和臨床中藥毒

理學. 香港商務印書館, 第一版, 2009. 中國香港. pp394.

9. 楊國祥，吳仲伯, 張大年，金建民，馮奕斌.《滇南本草》附方的研究. 雲南科技出版社，第一版, 1993. 中國

昆明. pp319.

Documents

Dr Feng, Yibin - 香港大學中醫藥學院 20180110.pdfof Integrative Medicine (IF 1.059), Journal of Alternative and Complementary Medicine (IF1.464), Molecular and Cellular Biochemistry